JPRN-jRCT2080224086终止1 期
An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours
ippon Boehringer Ingelheim Co., Ltd.0 个研究点目标入组 37 人开始时间: 2018年10月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •* Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy. Patient must have measurable or evaluable lesions (according to RECIST 1.1).
- •* Eastern Cooperative Oncology Group score of 0 or 1
- •* Adequate organ function at the liver, kidneys and bone marrow
排除标准
- •* Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening.
- •* Previous or concomitant malignancies other than the one treated in this trial within the last 2 years.
- •* Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
研究者
相似试验
进行中（未招募）
1 期
A study to find and investigate a safe dose of BI 836858 in combination with decitabine for patients with acute myeloid leukemia (AML)patients with acute myeloid leukemiaMedDRA version: 19.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2015-002892-30-ESBoehringer Ingelheim España, S.A.200
进行中（未招募）
1 期
A study to find and investigate a safe dose of BI 836858 in combination with decitabine for patients with acute myeloid leukemia (AML)patients with acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2015-002892-30-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.200
进行中（未招募）
1 期
A study to find and investigate a safe dose of BI 836858 in combination with decitabine for patients with acute myeloid leukemia (AML)patients with acute myeloid leukemiaMedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2015-002892-30-DEBoehringer Ingelheim Pharma GmbH & Co. KG220
进行中（未招募）
不适用
An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatmentEUCTR2007-005684-10-DEBoehringer Ingelheim Pharma GmbH & Co. KG169
进行中（未招募）
不适用
An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatmentPreviously untreated acute myeloid leukaemia in adult patients that are not eligiblefor intensive treatmentMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2007-005684-10-ATBoehringer Ingelheim RCV GmbH & Co KG169